Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Valbiotis SA ( (FR:ALVAL) ) just unveiled an announcement.
Valbiotis has released its half-year liquidity contract report showing changes in its liquidity account managed by Portzamparc. As of December 31, 2024, the account held 27,432 Valbiotis shares and 33,082.84 euros, indicating an increase in cash and a decrease in shares compared to the previous half-year. This report provides stakeholders insight into the company’s financial management and stock market activities.
More about Valbiotis SA
Valbiotis is a French scientific research laboratory that specializes in the commercialization of scientifically validated dietary supplements aimed at preventing metabolic and cardiovascular diseases, as well as promoting optimal daily health.
YTD Price Performance: 5.84%
Average Trading Volume: 2,394
Technical Sentiment Consensus Rating: Buy
Current Market Cap: €24.15M
For a thorough assessment of ALVAL stock, go to TipRanks’ Stock Analysis page.
